This blog was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches features of LifeSciVC. A lot has been written about the biotech talent war in the Boston area including the availability of talent as

This blog was written by Samantha Truex, CEO of Quench Bio and Atlas Entrepreneur-in-Residence, as part of the From The Trenches feature of LifeSciVC. In early September, I saw my two teenagers off to new destinations where they will live

This blog was written by Adam Rosenberg, CEO of Rodin Therapeutics, as part of the From The Trenches feature of LifeSciVC. After decades of challenges in neuroscience research and development, there is new hope that we can design better clinical

2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6 years. With lots of pundits

After last year’s inaugural success, we’re excited for 2019’s Science2Startup conference in April 2019, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities. Working with a steering committee comprised of Atlas,

This blog is written by Tom Hughes, CEO of Navitor Pharma, as part of the From The Trenches feature of LifeSciVC. We finally are beginning to understand the biological basis of aging and age-related diseases, making the discovery of new

This blog was written by Deanna Petersen, CBO of AVROBIO, as part of the From The Trenches feature of LifeSciVC. As with most professions – especially those that involve longer-term outcomes – the way people get good at BD is

The dreaded “lockup expiry” is something all newly-minted public biotechs begin to worry about shortly after their offerings. The fear seems reasonable: venture investors and other large shareholders, now free to trade, dump large amounts of stock into the market

This post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC When I first moved from the UK to the US, I told my parents that there was more biotech

The biotech IPO market continues to march forward, with five new offerings expected to price in the next week or so. Investor demand for stories advancing novel innovative therapies remains at historic levels – extending what is now over a

The biotech sector is unique relative to the rest of the stock market in many ways, but one that is often overlooked: its expansionary public equity market footprint. It’s been well appreciated by market analysts that the universe of U.S.

Biotech is booming, with eye-popping new financings seemingly announced daily. The sector is having an epic year for startup fundraising, breaking records for what will end up as the most active private biotech financing year ever. Although overall sentiment in